Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced interim Phase 2 results for its investigational mRNA therapeutic ARCT-810 in ornithine transcarbamylase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE